Navigation Links
Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
Date:3/9/2009

KENILWORTH, N.J., March 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) will not present at the Barclays Capital Global Healthcare Conference in Miami, on Tuesday, March 10, as previously planned. We will be participating in various investor and employee communications related to the merger agreement with Merck announced earlier today, and therefore, will not be able to attend the conference.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
2. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
3. Schering-Plough Selects Benefit Advocates for Health Advocacy
4. Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
5. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
6. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
7. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
8. Schering-Plough to Webcast R&D Update Meeting
9. Physicians Rank Schering-Ploughs Marketing Messages for Asmanex as the Most Appealing in the Asthma Drug Market
10. Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
11. Schering-Plough Reports Financial Results for Third Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: